deep science - · pdf filedeep science meets pure ... information in the presentation is not...

Deep Sciencemeets pure imagination

Daphne Zohar | Co-Founder & CEO | 18 November 2015

Forward Looking StatementThe following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by PureTech Health plc (the "Company"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below.

THIS DOCUMENT AND THE PRESENTATION IS NOT A PROSPECTUS. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract whatsoever relating to any securities.

The Presentation is being made, supplied and directed only at persons in member states of the European Economic Area who are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive and, additionally in the United Kingdom, only to those qualified investors who (a) are persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) (investment professionals) or (b) fall within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations etc.) (all such persons being "Relevant

Persons"). Any person who is not a Relevant Person may not attend the Presentation and should not act or rely on this document or any of its contents. Any investment or investment activity to which the Presentation relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. The term "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing regulations in each member state of the European Economic Area.

The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law or regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such

parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation.

Nothing in the Presentation is, or should be relied on as, a promise or representation as to the future. The Presentation includes certain statements, estimates, opinions and projections provided by the Company in relation to strategies, plans, intentions, expectations, objectives and anticipated future performance of the Company and its subsidiaries. By their nature, such statements, estimates, opinions and projections involve risk and uncertainty since they are based on various assumptions made by the Company concerning anticipated results which may or may not prove to be correct and because they may relate to events and depend on circumstances that may or may not occur in the future and may be beyond the Company’s ability to control or predict. No representations or warranties of any kind are made by any person as to the accuracy of such statements, estimates, opinions or projections, or that any of the events expressed or implied in any such statements, estimates or projections will actually

occur. The Company is not under any obligation, and expressly disclaims any intention, to update or revise any such statements, estimates, opinions or projections following the date of this Presentation. No statement in the Presentation is intended as a profit forecast or a profit estimate.

Certain industry and market data contained in this Presentation has come from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the

Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice.

The Presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (ii) you have read and agree to comply with the contents of this notice.

| 2

Tackling big healthcare problems in an unexpected way

PureTech – Who we are

PureTech (PRTC.L) is a

London Stock Exchange

Main Market listed

Healthcare Company …

… with an advanced pipeline

of programs, each targeting

multi-billion dollar markets …

… emerging from a rigorous

process by a team of world

renowned experts, and

externally validated

SUCCESSFUL IPO - $196M

Priced c.68M shares at 160p

Exercised c.10 million shares overallotment

Multiple times oversubscribed

INVESTOR BASE

Majority of shares held by long-term sophisticated fund managers

| 3



MULTI-BILLION DOLLAR MARKETS

Hair restoration

surgeries

Obesity cost to

healthcare system

Depression drugs

by 2017

$2B $190B $13B

Schizophrenia

market leader

sales

ADHD market

by 2020

CD and UC

costs to

healthcare

system

$6B $10B $6B



Main Market listed




multi-billion dollar markets…





| 4

ADVANCED PIPELINE



UNBIASED AND RIGOROUS PROCESS

2-4New

companies

per year

10-15Concept

phase

initiatives

~650Technologies

reviewed per

year

EXTERNAL VALIDATION

6Partnerships/

Collaborations

>110Patents &

patent

applications

| 5



Main Market listed




multi-billion dollar markets…





Note: Apple, Pepsico, Nestle, Medtronic, Boston Scientific and Novartis are included here to describe industry trends, and do not imply a relationship with PureTech

7

PHARMA COMPANIES

MEDICAL DEVICE COMPANIESTECH COMPANIES

FOOD COMPANIES

A new era of healthcare needs a new type of healthcare company

Healthcare is Changing

| 6

| 7

DAPHNE ZOHARCo-Founder & CEO Successful entrepreneur

RAJU KUCHERLAPATI, PHDHarvard, Co-founder of Millennium & Abgenix

DAME MARJORIE SCARDINOFormer CEO Pearson, MacArthur Foundation

Chair, Twitter Board, London School of Hygiene

ROBERT HORVITZ, PHDMIT, Nobel Prize in Medicine &

Co-founder of Epizyme

JOI ITOMIT Media Lab Director &

early investor in Twitter, Kickstarter

CHRISTOPHER VIEHBACHERFormer CEO & board member at Sanofi

JOHN LAMATTINA, PHDFormer President of Pfizer Global R&D

BEN SHAPIRO, MDFormer EVP of Research at Merck

ROBERT LANGER, ScDMIT, Co-founder of >20 biotech companies

Executive Vice President, Legal, Finance and Operations

Executive Vice President, Science & Technology

Executive Vice President, Company Creation

PureTech Board & Team

Executive Vice President, Chief Financial Officer

66 TEAM MEMBERS, many from top-tier institutions with cross disciplinary expertise

Senior Vice President, Investor Relations & Communications

PureTech Operating Companies

Tal – Non-invasive, rapidly acting treatment for depression

Vedanta Biosciences – Modulating the human microbiome

Karuna – Innovative therapy for the treatment of schizophrenia

Follica – Treatment for male and female pattern baldness

Entrega – Oral delivery of proteins, peptides, and magnetic nanoparticles

Akili – Rx video game platform for cognitive disorders

SOURCING PRECLINICAL CLINICAL

Gelesis – Encapsulated device for the treatment of obesity/prediabetes

Growth-stage Pipeline

| 8Note: Descriptions above reference to the potential attributes and characteristics of each therapy/product candidate which are subject to further development and

regulatory approval









Vedanta – Microbiome therapies

| 9



Note: Descriptions above reference to the potential attributes and characteristics of each therapy/product candidate which may be subject to further development

and regulatory approval

PureTech Operating CompaniesVedanta Biosciences

| 10

“An important step

forward in

microbiome-

based medicine”

Honda et al., 2011

“A big step

forward in

understanding

how the

microbiota

shapes the

host immune

system"


| 11

van Nood et al. NEJM 2013

Proportion of patients cured with fecal transplantation ~94%

vs ~30% with standard of care (vancomycin)

“Patients with life-

threatening gut

infections can be

cured by receiving

intestinal bacteria

from a healthy donor”


| 12

Vedanta IP Position

PureTech Operating CompaniesGrowth Stage

Vedanta BiosciencesModulating the human microbiome

Lead product has

demonstrated

preclinical efficacy

for IBD and allergy

Science & Nature

publications

$339M deal with J&J

MILESTONES ACHIEVED

EXPECTED MILESTONES & TIMING

MARKET POTENTIAL

Human trials in

multiple programs

2016/2017

Seeking to address

billion dollar

markets in auto-

immune disorders,

e.g., IBD, allergy,

infectious diseases

incl. C. Difficile

| 13




Gelesis – Encapsulated device for the treatment of obesity

| 14










PureTech Operating CompaniesGelesis

| 15

How it works

1

4

2

5 6

3

Composed of two food ingredients crosslinked to form a new chemical entity

PureTech Operating CompaniesGelesis

| 16

-12%

-10%

-8%

-6%

-4%

-2%

0%

0 1 2 3

Me

an

Bo

dy

We

igh

t %

Lo

ss

Months on Therapy

Gelesis100 2.25 g ITT

PopulationGelesis100 2.25 g

Prediabetics

Total Body Weight Loss Over 3

Months*

Note: Placebo-adjusted 3 month weight loss was

2% & 5.3% for all ITT Population & prediabetics, respectively.

128 subject, 3-month randomised double-blind placebo-controlled study

Statistically significant

weight loss in overweight

and obese patients,

including prediabetics

Strong safety profile


GelesisEncapsulated device for the treatment of obesity/prediabetes

Statistically

significant weight

loss in double-blind

placebo controlled

trial

Majority conversion

of pre-diabetics to

normal glycaemia

Growth Stage

MILESTONES ACHIEVED


MARKET POTENTIAL

Gelesis200 POC trial

for glycemic control/

prediabetes results in

2H 2016

Gelesis100 pivotal

trial for weight loss

results in 2017

Gelesis100 Potential

launch in 2018

1.9B people globally

are overweight or

obese

86M prediabetic

patients in US

| 17Note: Proof of Concept (POC)




Akili – Cognitive disorder video game platform

Gelesis – Encapsulated device for the treatment of obesity/prediabetics

| 18









PureTech Operating CompaniesAkili

| 19

PureTech Operating CompaniesAkili

| 20

Project: EVO Clinical Programs

ADHD Pilot Study results announced 28 October 2015


AkiliRx video game platform for cognitive disorders

Proof of concept

data published in

Nature

Positive ADHD

clinical data

Collaboration/

investors: Pfizer,

Autism Speaks, Shire

MILESTONES ACHIEVED


MARKET POTENTIAL

ADHD pivotal study

to be initiated in

coming months

Akili/Pfizer Alzheimer’s

pilot study read-out

in 2016

Potential product

launch in 2017

Seeking to address

ADHD market

projected to be

$10B by 2020

| 21




Follica – Alopecia treatment

| 22


Gelesis – Encapsulated device for the treatment of obesity/prediabetics








PureTech Operating CompaniesFollica

| 23

Insert image

VALIDATION FOR HAIR FOLLICLE NEOGENESISPreclinical and clinical studies support skin disruption for hair follicle neogenesis & hair growth

1. Ito M., Yang Z., Andl T. Cui C, Kim N, Millar SE, Cotsarelis G. Nature. 2007;447(7142):316–320.

2. Example quantified neogenic follicle as targets for pharmacologic modulation &hair repopulation in AGA . Source:

Follica internal Clinical R&D Findings – Fol-002(2008, unpublished)

3. Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. Int J Trichology. 2013;5:6–11.

Academic third-party

published research

demonstrates new

human hair growth using

Follica’s approach3

Insert imageInsert image

Follica’s 3 clinical

studies demonstrate

growth of de novo

hair follicles in humans2

PureTech Operating CompaniesFollica

| 24


FollicaTreatment for male and female pattern baldness

Demonstration of

follicular neogenesis

published in Nature

Creation of new

human hair follicles

& hair observed in 3

human studies

MILESTONES ACHIEVED


MARKET POTENTIAL

Registration office-

based procedure

study 2016

(readout 2017)

Potential product

launch in 2018

65M eligible

patients in US

| 25

Neuroscience MetabolismOncology/

Cell SignalingImmunology/ inflammation

Unexpected combinations

Drug-like effect without the drug

Bio-inspired engineering

Microbiome

Karuna Follica

Entrega

CommenSe

Synthetic biology

Next frontier

immuno-

oncology

DiabetesTargeting

inflamed tissue

Microbiome

and drugs

Infectious

disease and

drug resistance

| 26


Vedanta Bio.

Average ownership of companies = 75%

Note: Partial company listing; avg. ownership as of Aug 2015

Akili

Tal

Sonde Sleep

Gelesis

Launching 2-4 companies per year

27

Note: PureTech formal relationships are with individual advisors.

| 27

Scientific Revolutionsoften start as an idea between two friends

Driving Growth and Development

| 28

3Pivotal or registration

study read-outs

6Clinical Proof of

Concept

study read-outs

1H 2016 2H 2016

Read-out of Tal 90-patient confirmatory

proof of concept study

Read-out of Akili ADHD pivotal study

Potential start of first-in-human study for

Vedanta’s lead assetRead-out of Entrega large animal proof of concept study

Read-out of 60-patient KarXT proof

of concept

2H 2017

Read-out of 336+ patient Gelesis U.S. pivotal study

Initiate multi-site clinical study

1H 2017

Read-out of Follica registration study

Akili ADHD product potential launch

Read-out of PIb study

Note: Items in this timeline relate to an expected or potential milestone event which may or may not occur, depending on circumstances

Read-out of Gelesis200 proof of

concept study

Read-out of Akili Pfizer

Alzheimer’s study

Read-out of first pilot study

40Driving Long-term Sustainable Growth

12 innovative companies

approaching key milestones

LONG TERM VISION

| 29

Building a major healthcare company, tackling fundamental

medical needs with a strong pipeline of medicines that have the potential to impact billions

of patients

12 innovative companies

approaching key milestones

| 30

Questions?

Save the date:

Capital Markets Day, London 10 May 2016

@PureTechH @DaphneZoharPureTechHealth.com

deep science - · pdf filedeep science meets pure ... information in the presentation is not...

Documents